Skip to main content
. 2023 Oct 30;14:1231043. doi: 10.3389/fendo.2023.1231043

Figure 2.

Figure 2

Clinical pathway of diagnosis and management for patients with congenital hyperinsulinism (CHI). Clinical decisions hinge on criteria such as diazoxide responsiveness, genetic investigations, 18 Fluoro Dopa PET-CT/MR imaging and response to medical therapy.